Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia
Measurable residual disease (MRD) is a well-known independent prognostic factor in acute leukemias, and multicolor flow cytometry (MFC) is widely used to detect MRD. MFC is able not only to enumerate MRD accurately but also to describe an antigen expression profile of residual blast cells. However,...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/1/21 |
| _version_ | 1797626058314350592 |
|---|---|
| author | Yulia Davydova Irina Galtseva Nikolay Kapranov Ksenia Nikiforova Olga Aleshina Yulia Chabaeva Galina Isinova Ekaterina Kotova Andrey Sokolov Vera Troitskaya Sergey Kulikov Elena Parovichnikova |
| author_facet | Yulia Davydova Irina Galtseva Nikolay Kapranov Ksenia Nikiforova Olga Aleshina Yulia Chabaeva Galina Isinova Ekaterina Kotova Andrey Sokolov Vera Troitskaya Sergey Kulikov Elena Parovichnikova |
| author_sort | Yulia Davydova |
| collection | DOAJ |
| description | Measurable residual disease (MRD) is a well-known independent prognostic factor in acute leukemias, and multicolor flow cytometry (MFC) is widely used to detect MRD. MFC is able not only to enumerate MRD accurately but also to describe an antigen expression profile of residual blast cells. However, the relationship between MRD immunophenotype and patient survival probability has not yet been studied. We determined the prognostic impact of MRD immunophenotype in adults with B-cell acute lymphoblastic leukemia (B-ALL). In a multicenter study RALL-2016 (NCT03462095), 267 patients were enrolled from 2016 to 2022. MRD was assessed at the end of induction (day 70) in 94 patients with B-ALL by six- or 10-color flow cytometry in the bone marrow specimens. The 4 year relapse-free survival (RFS) was lower in MRD-positive B-ALL patients [37% vs. 78% (<i>p</i> < 0.0001)]. The absence of CD10, positive expression of CD38, and high expression of CD58 on MRD cells worsened the 4 year RFS [19% vs. 51% (<i>p</i> = 0.004), 0% vs. 51% (<i>p</i> < 0.0001), and 21% vs. 40% (<i>p</i> = 0.02), respectively]. The MRD immunophenotype is associated with RFS and could be an additional prognostic factor for B-ALL patients. |
| first_indexed | 2024-03-11T10:05:13Z |
| format | Article |
| id | doaj.art-bf99ee253c6442009a5b0e554db294da |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T10:05:13Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-bf99ee253c6442009a5b0e554db294da2023-11-16T15:07:45ZengMDPI AGDiagnostics2075-44182022-12-011312110.3390/diagnostics13010021Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic LeukemiaYulia Davydova0Irina Galtseva1Nikolay Kapranov2Ksenia Nikiforova3Olga Aleshina4Yulia Chabaeva5Galina Isinova6Ekaterina Kotova7Andrey Sokolov8Vera Troitskaya9Sergey Kulikov10Elena Parovichnikova11National Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaNational Medical Research Center for Hematology, 125167 Moscow, RussiaMeasurable residual disease (MRD) is a well-known independent prognostic factor in acute leukemias, and multicolor flow cytometry (MFC) is widely used to detect MRD. MFC is able not only to enumerate MRD accurately but also to describe an antigen expression profile of residual blast cells. However, the relationship between MRD immunophenotype and patient survival probability has not yet been studied. We determined the prognostic impact of MRD immunophenotype in adults with B-cell acute lymphoblastic leukemia (B-ALL). In a multicenter study RALL-2016 (NCT03462095), 267 patients were enrolled from 2016 to 2022. MRD was assessed at the end of induction (day 70) in 94 patients with B-ALL by six- or 10-color flow cytometry in the bone marrow specimens. The 4 year relapse-free survival (RFS) was lower in MRD-positive B-ALL patients [37% vs. 78% (<i>p</i> < 0.0001)]. The absence of CD10, positive expression of CD38, and high expression of CD58 on MRD cells worsened the 4 year RFS [19% vs. 51% (<i>p</i> = 0.004), 0% vs. 51% (<i>p</i> < 0.0001), and 21% vs. 40% (<i>p</i> = 0.02), respectively]. The MRD immunophenotype is associated with RFS and could be an additional prognostic factor for B-ALL patients.https://www.mdpi.com/2075-4418/13/1/21flow cytometryimmunophenotypemeasurable residual diseaseacute lymphoblastic leukemia |
| spellingShingle | Yulia Davydova Irina Galtseva Nikolay Kapranov Ksenia Nikiforova Olga Aleshina Yulia Chabaeva Galina Isinova Ekaterina Kotova Andrey Sokolov Vera Troitskaya Sergey Kulikov Elena Parovichnikova Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia Diagnostics flow cytometry immunophenotype measurable residual disease acute lymphoblastic leukemia |
| title | Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia |
| title_full | Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia |
| title_fullStr | Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia |
| title_full_unstemmed | Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia |
| title_short | Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia |
| title_sort | immunophenotype of measurable residual blast cells as an additional prognostic factor in adults with b cell acute lymphoblastic leukemia |
| topic | flow cytometry immunophenotype measurable residual disease acute lymphoblastic leukemia |
| url | https://www.mdpi.com/2075-4418/13/1/21 |
| work_keys_str_mv | AT yuliadavydova immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT irinagaltseva immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT nikolaykapranov immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT ksenianikiforova immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT olgaaleshina immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT yuliachabaeva immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT galinaisinova immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT ekaterinakotova immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT andreysokolov immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT veratroitskaya immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT sergeykulikov immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia AT elenaparovichnikova immunophenotypeofmeasurableresidualblastcellsasanadditionalprognosticfactorinadultswithbcellacutelymphoblasticleukemia |